Sera Prognostics (SERA) Revenue & Revenue Breakdown
Sera Prognostics Revenue Highlights
Latest Revenue (Y)
$77.00K
Latest Revenue (Q)
$24.00K
Sera Prognostics Revenue by Period
Sera Prognostics Revenue by Year
Date | Revenue | Change |
---|---|---|
2024-12-31 | $77.00K | -74.84% |
2023-12-31 | $306.00K | 14.18% |
2022-12-31 | $268.00K | 226.83% |
2021-12-31 | $82.00K | 228.00% |
2020-12-31 | $25.00K | -30.56% |
2019-12-31 | $36.00K | - |
Sera Prognostics generated $77.00K in revenue during NA 2024, up -74.84% compared to the previous quarter, and up 213.89% compared to the same period a year ago.
Sera Prognostics Revenue by Quarter
Date | Revenue | Change |
---|---|---|
2024-12-31 | $24.00K | -17.24% |
2024-09-30 | $29.00K | 20.83% |
2024-06-30 | $24.00K | 100.00% |
2024-03-31 | - | -100.00% |
2023-12-31 | $41.00K | -2.38% |
2023-09-30 | $42.00K | -65.85% |
2023-06-30 | $123.00K | 23.00% |
2023-03-31 | $100.00K | 53.85% |
2022-12-31 | $65.00K | -25.29% |
2022-09-30 | $87.00K | 11.54% |
2022-06-30 | $78.00K | 105.26% |
2022-03-31 | $38.00K | 46.15% |
2021-12-31 | $26.00K | 13.04% |
2021-09-30 | $23.00K | 15.00% |
2021-06-30 | $20.00K | 53.85% |
2021-03-31 | $13.00K | 116.67% |
2020-12-31 | $6.00K | 20.00% |
2020-09-30 | $5.00K | -16.67% |
2020-06-30 | $6.00K | -25.00% |
2020-03-31 | $8.00K | - |
Sera Prognostics generated $24.00K in revenue during Q4 2024, up -17.24% compared to the previous quarter, and up 57.14% compared to the same period a year ago.
Sera Prognostics Peer Comparison by Revenue
Ticker | Company | Last Year Revenue | Last Quarter Revenue |
---|---|---|---|
FONR | FONAR | $102.88B | $2.02M |
CSTL | Castle Biosciences | $332.07M | $87.99M |
XGN | Exagen | $55.64M | $15.50M |
RPID | Rapid Micro Biosystems | $28.05M | $8.22M |
TCRX | TScan Therapeutics | $2.82M | $665.00K |
SERA | Sera Prognostics | $77.00K | $24.00K |
RNAZ | TransCode Therapeutics | - | - |
ELEV | Elevation Oncology | - | - |
UNCY | Unicycive Therapeutics | - | - |